| 0.6021 0 (0%) | 04-19 11:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.36 |
1-year : | 37.53 |
| Resists | First : | 31.13 |
Second : | 32.13 |
| Pivot price | 30.7 |
|||
| Supports | First : | 29.5 |
Second : | 24.54 |
| MAs | MA(5) : | 30.45  |
MA(20) : | 30.51 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 29.1 |
D(3) : | 31.4 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 32.45 | Low : | 26.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ECO ] has closed above bottom band by 41.7%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 30.67 - 30.82 | 30.82 - 30.95 |
| Low: | 29.63 - 29.79 | 29.79 - 29.95 |
| Close: | 30.27 - 30.54 | 30.54 - 30.79 |
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
Mon, 07 Aug 2023
EV Biologics Appoints Senior Investment Banker as Corporate Finance Director - Yahoo Canada Finance
Thu, 18 Oct 2018
US-Traded, Low Float Chinese Stocks Are Going Crazy - EV Biologics (OTC:YECO) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 63.5 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 53 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 35.1 % |
| Operating Margin | 36.9 % |
| Return on Assets (ttm) | 10.8 % |
| Return on Equity (ttm) | 34.9 % |
| Qtrly Rev. Growth | -16.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 12.83 |
| EBITDA (p.s.) | 7.5 |
| Qtrly Earnings Growth | -56.1 % |
| Operating Cash Flow | 174 (M) |
| Levered Free Cash Flow | 120 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 2.38 |
| Price to Cash Flow | 5.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|